RGA Reinsurance Group of America, Incorporated
Reinsurance Group of America, Incorporated provides life and health, and asset-intensive reinsurance in the United States, Latin America, Canada, Europe, the Middle East, Africa, Asia, and Australia. It offers individual and group life and health, disability, long-term care, and critical illness reinsurance; and financial solutions, such as asset-intensive reinsurance, longevity reinsurance, stable value products, pension risk transfer transactions, and capital solutions. The company also provides reinsurance for mortality, morbidity, lapse, and investment-related risks; coinsurance of payout annuities; underwritten annuities; funding agreement backed note program and other capital motivated solutions; and superannuation. Reinsurance Group of America, Incorporated was founded in 1973 and is headquartered in Chesterfield, Missouri.…
Industry Peers
Insurance - ReinsuranceKey Statistics
About Reinsurance Group of America (NYSE: RGA)
›
Reinsurance Group of America (NYSE: RGA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Insurance - Reinsurance industry, part of the Financial Services sector, and reports about 4,300 employees.
The shares were at 268.03 USD on 19 November 2026, up 43.3% over 52 weeks. Its 52-week range is 182.73 USD to 277.15 USD: the price is 3.3% below the high and 46.7% above the low.
At a market capitalisation of 17.43B USD, it trades at 10.4 times trailing earnings and 8.7 times forward earnings. The median trailing P/E of its 12 largest Insurance - Reinsurance peers is 9.2, a premium of 13% for RGA. It pays a dividend yielding 1.48% (it pays out 15% of its earnings), against a median of 4.20% among the dividend payers in that peer group.
Reinsurance Group of America reports return on equity of 8.8%, an operating margin of 9.4% and revenue up 21.7% year over year.
Its debt exceeds its cash by 269.00M USD, a debt-to-equity ratio of 0.42. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 297.78 USD is 11.1% above the current price. The next earnings report is expected on 11 February 2027.